A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.

A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema. Br J Dermatol. 2019 Mar;180(3):435-437 Authors: Weidinger S, Apfelbacher C PMID: 30821391 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30821391?dopt=Abstract

Source: The British Journal of Dermatology - February 28, 2019 Category: Dermatology Authors: Weidinger S, Apfelbacher C Tags: Br J Dermatol Source Type: research

More News: Dermatology | Eczema | Skin | UK Health